+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia



Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia



Zhonghua Xue Ye Xue Za Zhi 30(7): 440-442



To report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL). CHDT was administered 1.25 g orally three times a day after meal for three days, then the dosage was gradually increased to 7.5 g/d. One hundred and ninety-three patients achieved complete remission (CR), 78.8% of whom in 30 to 60 days with an average time of 44.3 d. No serious infection, bleeding or DIC occurred during the treatment course. The major adverse effects were gastrointestinal symptoms. There was no change in lanine transaminase, urea, creatinine or electrocardiographic QTc interval in 110 APL patients observed before and after the treatment. CHDT therapy is a modality of higher CR rate, good safety and tolerance without bone marrow suppression for APL patients.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 052269155

Download citation: RISBibTeXText

PMID: 19954593


Related references

Effect of post-remission therapy mainly with compound huangdai tablet on long-term survival of patients with acute promyelocytic leukemia. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 30(12): 1253-1256, 2013

Effects of all-trans retinoic acid and compound huangdai tablet sequential maintenance treatment on the long-term efficacy of acute promyelocytic leukemia patients. Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi 32(11): 1473-1476, 2014

Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 94(10): 3315-3324, 1999

Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia. Hematologic Pathology 3(1): 23-28, 1989

Congestive heart failure during induction with anthracycline-based therapy in patients with acute promyelocytic leukemia. Journal of Community and Supportive Oncology 12(11): 390-393, 2015

Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group. Cancer 76(4): 602-608, 1995

Predictive factors of bleeding and thrombosis during induction therapy in acute promyelocytic leukemia-a single center experience in 34 patients. Thrombosis Research 116(2): 109-114, 2005

Molecular remission of PML/RARalpha after double induction therapy and ALL-trans retinoic acid in patients with acute promyelocytic leukemia. Annals of Hematology 77(SUPPL 2): S175, 1998

Complete remission in acute promyelocytic leukemia despite persistence of abnormal bone marrow promyelocytes during induction therapy: experience in 34 patients. Blood 71(3): 690-696, 1988

Phase III randomized study of all-trans retinoic acid vs daunorubicin and cytosine arabinoside as induction therapy and ATRA vs observation as maintenance therapy for patients with previously untreated acute promyelocytic leukemia. Blood 86(10 SUPPL 1): 125A, 1995

Low relapse rate after intensified induction therapy including high dose ara-C and all-trans retinoic acid in patients with acute promyelocytic leukemia. Blood 98(11 Part 1): 765a-766a, November 16, 2001

CNS relapse in a low risk acute promyelocytic leukemia patient treated with ATRA-based regimen: is there a role for prophylactic CNS therapy in acute promyelocytic leukemia?. Indian Journal of Hematology & Blood Transfusion 25(3): 118-119, 2009

Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia. Haematologica 97(2): 227-234, 2012

Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation. APL Study Group. Acute promyelocytic leukemia. Leukemia 14(6): 1006-1013, 2000

Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. Cancer (Philadelphia) 76(4): 602-608, 1995